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The off-label use of drugs is common, particularly in 
paediatrics, where many drugs have yet to undergo the 
rigorous scrutiny demanded by authorities such as the 
Medicines Control Council (MCC) and the US Food and 
Drug Administration (FDA) before registration.1,2 Yet some 
drugs (e.g. paracetamol, salbutamol) are so commonplace in 
paediatric practice that it may come as a surprise that their 
use is indeed off-label in many circumstances. Problems may 
arise when an important drug in everyday (off-label) use is 
unexpectedly in short supply. An example is dinoprostone, 
marketed in South Africa as Prostin E2 by Pfizer South Africa 
(but curiously not listed on their website). Its registered 
use in South Africa is for induction of labour (as an oral 0.5 
mg tablet), yet it is commonly used in South Africa for the 
emergency maintenance of ductal patency in newborn babies. 
Dinoprostone
Dinoprostone is a naturally occurring prostaglandin E2 that 
binds and activates the PGE2 receptor. It is often used as an 
emergency treatment to maintain the patency of the ductus 
arteriosus (PDA) in neonates with duct-dependent lesions 
such as certain forms of cyanotic congenital heart disease (e.g. 
pulmonary atresia or transposition of the great arteries) and 
interruption or coarctation of the aorta. The birth incidence 
of these rapidly life-threatening lesions is 1.0 - 1.8/1 000 3 and 
administration of dinoprostone is life-saving, ‘buying time’ 
for the baby to be transferred to a referral centre for definitive 
establishment of pulmonary or aortic blood flow by systemic-
to-pulmonary shunt or arch repair, respectively. Without 
maintenance of ductal patency, duct-dependent babies rapidly 
become critically ill and die. 
Dinoprostone is also used for the longer-term maintenance 
of ductal patency in low-birth-weight infants with duct-
dependent pulmonary circulations but branch pulmonary 
arteries that are too small for immediate surgical placement of 
a systemic-to-pulmonary artery shunt.4 
For these applications, dinoprostone is usually administered 
as an oral medication. The 0.5 mg tablet is crushed and mixed 
with water and 0.125 mg aliquots (¼ tablet) are given to the 
infant by nasogastric tube every 30 - 60 minutes.4 The side-
effects are minimal, but include a small increase in body 
temperature (generally to less than 37.5°C) and loose stools. 
This simple method of administration is easily achievable 
by peripheral hospitals and delivery units, enabling rapid 
establishment of stable ductal patency before transfer to a 
tertiary referral centre. 
An alternative, intravenous PGE1 (alprostadil, Prostin 
VR), requires the placement of secure intravenous access 
for continuous infusion of alprostadil and close monitoring 
of respiratory effort. Intravenous PGE1 frequently causes 
apnoea requiring intubation and ventilation for safe transfer. 
Peripheral hospitals and delivery units are often not capable of 
such interventions and do not stock intravenous PGE1. There 
are no alternatives to maintain ductal patency.
The whistle-blower case
In January 2009 we received a call from a paediatrician at 
a regional hospital. A small infant with pulmonary atresia, 
dependent on a PDA for flow to his pulmonary arteries, 
required time to grow to sufficient size to enable the placement 
of a modified Blalock-Taussig shunt. After assessment at Red 
Cross War Memorial Children’s Hospital he had been returned 
to the regional hospital for growth,  receiving a quarter 
Prostin E2 tablet half-hourly for maintenance of his PDA. The 
hospital was about to run out of Prostin E2 and was unable 
to replenish the supply from local clinics or hospitals, since 
these had all also run out. No stocks were available from local 
suppliers. The baby was transferred back to Red Cross Hospital 
on intravenous alprostadil, and required early placement of 
a systemic-to-pulmonary artery shunt. The procedure was 
complicated by early shunt stenosis and re-operation was 
required for shunt revision, which could have been avoided 
had he been allowed to grow until the vessels were larger, 
lessening the risk of shunt thrombosis.
ISSUES IN MEDICINE
Surprises of off-label drug use – where had all the Prostin 
gone?
Rik De Decker, Eugenie Gordon-Graham, Neil Seller, John Lawrenson
Rik De Decker is a senior specialist paediatric cardiologist and 
Eugenie Gordon Graham director of pharmaceutical services 
at Red Cross War Memorial Children’s Hospital, Cape Town.  
Neil Seller is a senior registrar in paediatric cardiology in 
the department of Paediatrics and Child Health, University 
of Stellenbosch. John Lawrenson is a senior lecturer in the 
Department of Paediatrics and Child Health at the University of 
Stellenbosch.
Corresponding author: R De Decker (rik.dedecker@uct.ac.za)
SAMJ FORUM
433
June 2009, Vol. 99, No. 6  SAMJ
Where had all the Prostin gone? 
Unbeknown to South African paediatric cardiologists and 
most pharmacists nationally, stocks of Prostin E2 had become 
critically depleted. Pfizer is said to have redesigned the 
packaging of Prostin E2, and stocks became depleted while 
awaiting re-registration with the Medicines Control Council. 
Why did Pfizer fail to inform paediatric cardiologists 
and pharmacists of an imminent and foreseeable shortage? 
Apparently Pfizer representatives had informed obstetric/
gynaecological practitioners, but according to their 
spokesperson they were ‘not allowed’ to discuss an off-label 
drug with paediatric cardiologists, despite the fact that Prostin 
E2 is the only oral dinoprostone available in South Africa and 
has been in use as outlined for many years. A rapid survey of 
all paediatric cardiac referral centres in South Africa revealed 
that this was a national problem in both the public and private 
health sectors. At the same time, Pfizer could not tell us with 
certainty when supplies would be resumed.
To their credit, when the potential impending crisis in 
congenital cardiac care was brought to Pfizer’s attention in 
mid-January 2009, they expedited the delivery of fresh stocks 
to suppliers, and by Monday 26 January the supply of Prostin 
E2 had resumed nationwide. Pfizer assured us that there was 
sufficient stock ‘for two years’ and that future supplies would 
be ‘uninterrupted’, but unfortunately were not prepared to give 
these assurances in writing. 
So ended a brief yet worrying period during which we could 
not ensure the safe transfer of neonates with duct-dependent 
congenital cardiac lesions and were having to start making 
difficult management decisions with regard to timing of 
their cardiac surgery. Nevertheless, it remains of concern that 
the supply of essential and life-saving drugs can be prone 
to sudden, unexpected interruptions; and perhaps more so 
that producers consider themselves legally constrained from 
disclosing imminent foreseeable drug supply interruptions if 
such drugs are used off-label. The reluctance of pharmaceutical 
companies to discuss issues pertinent to the use of off-label 
drugs – even urgent issues such as notification of interruption 
of supply – is grounds for much concern. It surprises us 
that medical practitioners working for this company are 
not prepared to inform colleagues – even ‘off the record’ – 
considering that Prostin is listed for paediatric use in the latest 
version of the essential drugs list for South Africa.5 
The FDA becomes permissive
In the USA, the FDA’s prohibition on pharmaceutical 
companies to inform medical practitioners of important 
changes in indications for off-label drugs has been judged in 
the US District Court of Columbia as unconstitutional, and the 
FDA’s restrictive stance vigorously criticised. The judgment 
included the statement: ‘In sum, the court finds that the 
restrictions in the Guidance Documents [of the FDA] are more 
extensive than necessary to serve the asserted government 
interest and that they unduly burden important speech.’6   In 
essence, the district court therefore had found that the FDA 
had violated the First Amendment of the US Constitution.  On 
appeal, the US Court of Appeals for the District of Columbia 
dismissed the finding of the district court  pertaining to the 
unconstitutionality of the FDA’s prohibitions on procedural 
grounds, since it ‘was not ripe for decision’, but noted that it 
‘certainly did not criticize the reasoning or conclusions of the 
district court’.7
Thereafter, the FDA reconsidered its role in the regulation 
of off-label drug use, suggesting ‘a more permissive attitude 
toward the promotion of off-label uses of drugs’.8 In its 
recently published ‘Guidance for Industry’ document9 the FDA 
recognises ‘that the public health can be served when health 
care professionals receive truthful and non-misleading scientific 
and medical information on unapproved uses of approved or 
cleared medical products’. 
Conclusion
While US law is not necessarily applicable in South Africa, 
surely common sense demands that in the interests of public 
health, information of a life-threatening shortage of any drug, 
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Pfizer South Africa welcome this article, which seeks 
to inform and protect the interests of both patients and 
physicians, and thank SAMJ for the opportunity to clarify 
some of the points made for the benefit of readers.
Product shortages do occur from time to time for a variety 
of reasons. In the case of Prostin E2 we found ourselves in 
an unfortunate situation whereby our third-party supplier 
ran out of stock. This was totally unexpected and, because 
they are a third-party supplier, resulted in our having to 
follow a number of different logistical as well as regulatory 
processes. 
Keeping patients and physicians informed and 
protecting their interests is of paramount importance to 
Pfizer South Africa, and we greatly appreciate feedback. 
We will incorporate De Decker et al.’s suggestions in our 
communications to ensure that all relevant health care 
professionals are promptly informed of such issues within 
the confines of the industry regulations, and assure readers 
of our commitment to providing uninterrupted access to 
our medicines for patients and physicians. 
Brian Daniel
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Pfizer South Africa
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even in off-label use, should be disseminated as widely as 
possible to relevant health professionals. This would allow 
clinicians and pharmacists to implement contingency plans 
and/or changes in management strategies in order to minimise 
potential loss of life or increased morbidity resulting from the 
shortage of the drug. 
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Dear Aunt Ethel,
During the second six months of internship at Groote Schuur 
Hospital, when we were covering four internal medicine wards 
divided between two firms, Toby called an informal meeting.
‘Look, I’m the only Jewish house officer among the six of 
us: Christmas means nothing to me. I’ll be on duty all day 
provided that I’m off for the Jewish holidays.’
This was a fair offer, so Toby duly celebrated his religious 
holidays free from any ward work or calls. The rest of us 
looked forward to a guaranteed Christmas off duty: festivities 
looked very promising as nurses and doctors were arranging 
an all-day party. However, a complication was brewing. Toby 
had become interested in a nurse who was a gentile – and an 
organiser of the Christmas entertainment. As this involvement 
progressed he sounded less and less convinced that Christmas 
meant nothing to him, and discussed mistletoe and mince-
pies in longing terms. There was also the matter of who might 
distract the lovely young lady in question during the festivities 
if he was slaving away all day on the ward. Eventually he put 
his cards on the table, choosing a good psychological moment: 
a seventh intern had been seconded to our wards. 
‘Look, Christmas now means more to me than I suspect it 
does to the majority of you. How about splitting the duties that 
day? Draw names out of a hat. 6 am to 6 am, four-hour shifts 
between six house-officers, the seventh has the day off.’
This was reasonable: personal conquests were non-existent; 
we liked Toby; we wanted his romance to succeed. In any 
case only four hours each, with an outside chance of none at 
all, seemed hardly a problem. Chutzpah baffles logic. Then the 
draw took place. Fair and square, Toby pulled the seventh 
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straw, and three of us landed prime time shifts. Mine was from 
2 pm to 6 pm.
Christmas was bedlam. After a quick ward round, I acted as 
Santa Claus to the four wards: only the most confused patient 
recognised her doctor. A patient with meningitis whom we 
had regretted resuscitating after he arrested proved not to be 
brain-dead: just stone-deaf. He roared with laughter at the little 
elasticised animal which Santa, on a whim, produced. Then I 
tore off to a farm an hour’s drive away to be Father Christmas 
again, on a blazing-hot day, wearing a mask that denied visual 
acuity, mounted side-saddle on a recalcitrant horse. I bolted an 
enormous roast-turkey dinner and screamed back into Cape 
Town in time for my shift. Things were hotting up on the 
wards after a peaceful morning. Admission after admission 
rolled in, preventing any easy departure at 6 pm: more like 
8.30. By then the all-day festivities were at an end.
Toby had had a great day and on the ward next morning, 
he asked how our Christmas had been. I recall a sardonic and 
laconic: ‘Nowell? Ja … Fine!’
He did have the decency to marry her.
I have been Father Christmas on many Yuletide occasions 
since, riding pillion on a motor-bike once, arriving in a speed-
boat on another stint. One did not really question why one 
went beyond the call of duty. Now at last I know the reason for 
the compulsion: it’s inborn, it’s genetic …
When I e-mailed Kit Vaughan to congratulate him on his 
biography of Allan Cormack, Imagining the Elephant, he told me 
about At the Heart of Healing, the recently published history of 
Groote Schuur Hospital’s first 70 years. With a holiday ahead, 
I bought a copy. Simultaneously my wife got a call from Jenny 
Still, a journalist and family friend in Cape Town. At a UCT 
summer-school lecture she’d seen a DVD of Dr Caldwell as 
Santa Claus at Groote Schuur Hospital.
It was in 1937, so it was not I: and it was New Somerset 
Hospital, not Groote Schuur: the former was closing as the 
latter was due to open. My father, as a ‘June bride’, had walked 
into history by being on the last resident staff of Somerset and 
the first of Groote Schuur: but I did not know about any Santa 
activities.
A night or two later I received a phone call from Howard 
Phillips, a professor in  the Department of Historical Studies at 
UCT and one of the chief authors of the book. Jenny Still had 
spoken to him after the lecture. He suspected that Santa Claus 
was my late father, and if so would I be interested in seeing 
some film footage? Since the upcoming holiday was in the 
Cape, I accepted with alacrity and met him a fortnight later in 
the UCT history building, where he showed me a DVD made 
from film footage taken by a nursing sister. This documented 
the transition from New Somerset Hospital to Groote Schuur as 
1937 ended and 1938 began. 
Although Father Christmas jumped around in a manner 
not reminiscent of my Dad, the jerky actions matched those of 
which his grandchildren complain regarding their father. When 
the unmasking came, there was my father, just as he looked in 
the photograph I have in my office: of the first resident staff of 
GSH. Our sons have an inherited white-bearded task ahead of 
them; and the book is well worth reading.
Yours affectionately
Robert-Ian
